Literature DB >> 9230741

Surfactant composition in infants and young children with cystic fibrosis.

J Hull1, M South, P Phelan, K Grimwood.   

Abstract

We tested the hypothesis that the composition of bronchial surfactant is normal in infants with cystic fibrosis (CF) in the absence of active lung disease but that it is altered by lower respiratory tract infection and inflammation. We examined the total phospholipid (PL), disaturated phospholipid (DSP), surfactant protein-A (SP-A), surfactant protein B (SP-B), and surface activity in bronchoalveolar lavage fluid from 27 subjects with CF whose mean age was 22.7 (SD 14.5) mo. Six infants with stridor served as non-CF controls. Twelve of the subjects with CF (CF-I group) had evidence of active pulmonary infection or inflammation which was absent in the remaining 15 subjects (CF-NI group). We found no differences in the surfactant composition or activity between controls and the CF-NI group. In contrast, the DSP/PL ratio was lower in the CF-I subjects than in both the CF-NI subjects (p = 0.05) and controls (p < 0.01) suggesting a disturbance of surfactant function. SP-A concentrations were higher in the CF-I group compared to the other two groups (p < 0.05). These results suggest that the bronchial surfactant of infants with CF is altered following lower airway infection and inflammation and is not a primary abnormality associated with this disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230741     DOI: 10.1164/ajrccm.156.1.9609090

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis.

Authors:  J D Antuni; S A Kharitonov; D Hughes; M E Hodson; P J Barnes
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 2.  Surfactant protein-A: new insights into an old protein--II.

Authors:  A R Kumar; J M Snyder
Journal:  Indian J Pediatr       Date:  1998 Nov-Dec       Impact factor: 1.967

3.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

Review 4.  Surfactant phospholipid metabolism.

Authors:  Marianna Agassandian; Rama K Mallampalli
Journal:  Biochim Biophys Acta       Date:  2012-09-29

Review 5.  Air pollution and epigenetics: effects on SP-A and innate host defence in the lung.

Authors:  Patricia Silveyra; Joanna Floros
Journal:  Swiss Med Wkly       Date:  2012-05-02       Impact factor: 2.193

6.  Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum.

Authors:  Keith H Turner; Aimee K Wessel; Gregory C Palmer; Justine L Murray; Marvin Whiteley
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

7.  Increased expression of surfactant protein A and D in rheumatoid arthritic synovial fluid (RASF).

Authors:  Orhan Kankavi
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

Review 8.  Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury.

Authors:  Patricia Silveyra; Joanna Floros
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

9.  Generation of lung epithelial-like tissue from human embryonic stem cells.

Authors:  Lindsey Van Haute; Gert De Block; Inge Liebaers; Karen Sermon; Martine De Rycke
Journal:  Respir Res       Date:  2009-11-05

10.  Staphylococcus aureus and Pseudomonas aeruginosa express and secrete human surfactant proteins.

Authors:  Lars Bräuer; Martin Schicht; Dieter Worlitzsch; Tobias Bensel; R Gary Sawers; Friedrich Paulsen
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.